Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of combining bortezomib with docetaxel in treating
patients who have advanced solid tumors. Bortezomib may stop the growth of tumor cells by
blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use
different ways to stop tumor cells from dividing so they stop growing or die. Combining
bortezomib with docetaxel may kill more tumor cells